AbbVie Inc (ABBV)
194.79
+2.89
(+1.51%)
USD |
NYSE |
Sep 27, 16:00
194.80
+0.01
(+0.01%)
After-Hours: 20:00
AbbVie SG&A Expense (Annual): 12.87B for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.87B |
| December 31, 2022 | 15.26B |
| December 31, 2021 | 12.35B |
| December 31, 2020 | 11.30B |
| December 31, 2019 | 6.942B |
| December 31, 2018 | 7.399B |
| December 31, 2017 | 6.295B |
| December 31, 2016 | 5.881B |
| Date | Value |
|---|---|
| December 31, 2015 | 6.387B |
| December 31, 2014 | 7.724B |
| December 31, 2013 | 5.352B |
| December 31, 2012 | 4.989B |
| December 31, 2011 | 5.894B |
| December 31, 2010 | 3.82B |
| December 31, 2009 | 3.349B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
6.942B
Minimum
2019
15.26B
Maximum
2022
11.74B
Average
12.35B
Median
2021
SG&A Expense (Annual) Benchmarks
| Amgen Inc | 6.179B |
| Johnson & Johnson | 20.11B |
| Eli Lilly and Co | 6.941B |
| Merck & Co Inc | 10.50B |
| Pfizer Inc | 14.77B |